HALIX provides viral vector and recombinant protein products. They leverage biopharmaceutical technologies and provide pharmaceutical documentation of cGMP production processes and the production of units required for clinical approval. Their services range from the first development steps to the start of commercial production after the registration of products.
Something looks off?